Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Trials & Filings in Brief: Sept. 30, 2013 | Contract Pharma

What are you searching for?

Sign in
Breaking News, Trials & Filings

Trials & Filings in Brief: Sept. 30, 2013

AcelRx, Alnylam, Astellas, Cardiome, DiaMedica, Halozyme, Immunomedics, Lion Biotech, Omeros, Tesaro, USB, Vertex

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

Phase I
DiaMedica diabetes treatment hits primary endpoints . . . read more

Halozyme gets positive PFS, OS results for PEGPH20 . . . read more

Immunomedics updates ADC results in metastatic colorectal cancer . . . read more

Tesaro begins dose-finding study of rolapitant . . . read more

Phase II
Alnylam completes Phase II enrollment for ATTR . . . read more

Lion’s metastatic melanoma treatment posts positive Phase II results . . . read more

Phase III
Astellas posts positive aspergillosis trial results . . . read more

Filings
AcelRx files NDA for analgesic Zalviso . . . read more

Brinavess approved in South Africa . . . read more

Omeros gets orphan status for PDE10 inhibitor . . . read more

UCB’s Cimzia approved for PsA . . . read more

Vertex files Kalydeco SNDA . . . read more

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics